Monday, August 3, 2026 · Covering: Fri–Mon
TL;DR
Big Tech earnings split the market on Friday: Amazon surged ~12% on AWS acceleration and Microsoft rose ~8%, while Apple fell ~8% despite a record quarter after warning on component shortages — the tape is rewarding visible AI returns and punishing bottlenecks. The Fed's hawkish hold (three dissents for a hike) keeps rate-cut hopes on ice, with all eyes on the July jobs report. Dealmaking stayed brisk into the weekend: Couche-Tard launched an ~$8.6B tender for Poland's Żabka, Select Medical completed a $3.9B management buyout with Welsh Carson, and ResMed carved out its MatrixCare software unit for $490M.
TOP 3 DEALS
DEAL 01
Consumer / Retail · Cross-Border
EQUITY VALUE~PLN 32.6B / ~$8.6B
STRUCTUREVoluntary tender (57% locked up)
FINANCINGJ.P. Morgan (lead arranger); NBC, Scotiabank (bookrunners)
M&A ADVISERSAdvisers TBD
Canadian convenience-store giant Alimentation Couche-Tard bid ~PLN 32/share for controlling ownership of Żabka, Poland's largest convenience chain, with sellers including CVC entity Heket already committed for ~57% of shares. After walking away from 7-Eleven, Couche-Tard is redeploying M&A firepower into a fast-growing European platform — funded entirely with committed debt.
Why it matters for recruiting: A clean example of a cross-border, all-debt-funded strategic tender offer where a sponsor (CVC) is the seller. Note the CEO's own comment that shareholders may push for a higher price — a live case study in tender mechanics, minority-holder leverage, and how a strategic acquirer competes with sponsors for scaled assets.
DEAL 02
Healthcare · Management Buyout
TRANSACTION VALUE~$3.9B ($16.50/share)
BUYERSOrtenzio & Jackson (management) + WCAS
PREMIUM~18% to pre-proposal close
ADVISERSCravath (legal, buyer); financial advisers TBD
Select Medical, a large operator of rehab and critical-illness recovery hospitals, went private in a buyout led by its own Executive Chairman and a senior executive alongside PE firm Welsh, Carson, Anderson & Stowe. It's an insider-led take-private — management partners with a sponsor to buy the company they run at $16.50/share.
Why it matters for recruiting: Management buyouts raise the conflict-of-interest issues bankers must manage — special committees, fairness opinions, and "go-shop" provisions all exist because insiders sit on both sides. Be ready to explain how a board protects minority shareholders when management is the buyer, a favorite topic for M&A interviews.
DEAL 03
Healthcare Software · Carve-Out
TRANSACTION VALUE~$490M cash
BUYERFrazier Healthcare Partners (PE)
SELLERResMed (NYSE: RMD)
ADVISERSAdvisers TBD
Medical-device maker ResMed agreed to sell MatrixCare, its long-term and post-acute care software business, to PE firm Frazier Healthcare Partners. It's a carve-out: ResMed sheds a non-core software unit to sharpen its device focus, while a specialist sponsor gets a standalone healthcare-IT platform to grow.
Why it matters for recruiting: Carve-outs are among the most technical M&A processes — you separate shared systems, people, and contracts (TSAs, stranded costs) to make a division stand alone. Understanding why a parent divests non-core assets and how a sponsor underwrites a carve-out is exactly the kind of "why this deal" reasoning banks probe.
SECTOR SIGNAL
DEFENSE / AEROSPACE
TransDigm's ~$1.07B buy of brazing-alloy maker Prince & Izant (announced late last week) underscores the ongoing PE-to-strategic pipeline in A&D components, where sole-source parts command premium multiples. PRNewswire ↗
TECH / TMT
The AI-returns divide sharpened: Amazon (+12%) proved capex is feeding faster AWS growth, while Meta and Alphabet were punished earlier in the week for spending without visible payback. Saxo ↗
INDUSTRIALS / ENERGY
KKR/ECP's ~$7.7B take-private of energy distributor DCC and Expand Energy's $1.25B buy of gas marketer Twin Eagle show sponsors and strategics both leaning into cash-generative energy infrastructure. Bloomberg ↗
HEALTHCARE
Beyond Select Medical and MatrixCare, Warburg Pincus and ADIA are reportedly nearing a $7B+ deal for specialty pharmacy PANTHERx Rare — sponsor appetite for healthcare services remains strong. LECO ↗
M&A / LEVERAGED FINANCE
Insider-led take-privates (Select Medical) and all-debt strategic tenders (Żabka) headline a market where committed financing is readily available even with the Fed on hold. The recurring theme across the week: sponsors and management teams are exploiting still-open credit markets to move assets off public exchanges. White & Case ↗
MARKET TONE
Earnings dispersion. Amazon +12% (AWS), Microsoft +8%, Apple −8% (record quarter but component-shortage warning) — the "Mag 7" is trading less like a bloc and more on individual execution. IBTimes ↗
Fed on hold, hawkish. Rates held at 3.50–3.75% with three dissents for a hike; markets have pared near-term cut expectations. CNBC ↗
Jobs in focus. Economists expected ~85k July payrolls after a weak 57k in June; the labor-market trend is the key input for the next Fed move. Bloomberg ↗
AI capex = the swing factor. Whether hyperscaler spending shows returns (Amazon) or not (Alphabet, Meta) is now the single biggest driver of mega-cap moves. Fortune ↗
Credit stays open. Fully committed debt behind Żabka and buyout leverage for Select Medical confirm financing conditions still support large deals. PRNewswire ↗
INTERVIEW ANGLE
TOPIC: HOW A BOARD HANDLES A MANAGEMENT BUYOUT
Select Medical's $3.9B take-private is a perfect prompt to show you understand M&A process and governance — not just valuation. The wrinkle: the buyers are the company's own Executive Chairman and a senior executive, partnering with sponsor Welsh Carson. That creates a conflict of interest, because insiders control information and sit on both sides of the table.
Special committee: the board forms a committee of independent directors, with its own legal and financial advisers, to negotiate against management on behalf of shareholders.
Fairness opinion: an independent bank opines that the $16.50/share price is fair — key evidence the board met its duty of care.
Market check / go-shop: the deal may include a window to solicit higher bids, testing whether the insider price is truly the best available.
How to bring it up: "The Select Medical MBO caught my eye — when management is the buyer, the interesting work isn't the model, it's the process: special committee, fairness opinion, go-shop. It's a good reminder that in M&A the banker's job is as much about protecting shareholders and managing conflicts as it is about the numbers."